Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

QUEBEC CITY--(BUSINESS WIRE)--IA FINANCIAL GROUP, ONE OF CANADA'S LEADING INDIVIDUAL INSURANCE PROVIDERS, ANNOUNCES THE LAUNCH OF THE WEB VERSION OF ITS EVO INSURANCE PLATFORM, ALREADY USED BY MORE THAN 30,000 FINANCIAL SECURITY ADVISORS ACROSS THE COUNTRY. THIS NEW VERSION MARKS AN IMPORTANT STEP IN THE SECTOR'S DIGITAL TRANSFORMATION, OFFERING AN EVEN MORE ACCESSIBLE, QUICKER AND INTUITIVE SOLUTIONDIRECTLY FROM A COMPUTER, TABLET OR PHONE. DESIGNED TO OPTIMIZE ADVISORS' DAY-TO-DAY ACTIVITIES.

IA FINANCIAL GROUP PROPELS ADVISORS' DIGITAL EXPERIENCE TO NEW HEIGHTS WITH THE LAUNCH OF THE WEB VERSION OF EVO INSURANCE

STRATEGY FOR SUSTAINABLE PROFITABLE GROWTH PROGRESSING AS PLANNED WITH IMPROVING REVENUE MIX AND AHEAD-OF-PLAN COST REDUCTIONS REPORTING SEGMENT FORMERLY KNOWN AS SHARED R&D RENAMED TO DISCOVERY & PRECLINICAL DEVELOPMENT ("D&PD") TO BETTER REFLECT STRATEGIC FOCUS GROUP REVENUES OF  371.2 M (-5%); D&PD (-11%) CONTINUES TO SEE SOFT DEMAND;JUST - EVOTEC BIOLOGICS ("JEB"; +16%) EXCEEDING EXPECTATIONS DRIVEN BY BROADENED CUSTOMER BASE KEY PROGRESS IN COLLABORATIONS WITH BRISTOL MYERS SQUIBB ("BMS") ON TARGETED PROTEIN DEGRADATION AND NEUROSCIENCE EVOLUTION OF STRATEGIC PARTNERSHIP WITH SANDOZ ANNOUNCED ON 30 JULY HAMBURG, DE / ACCESS NEWSWIRE / AUGUST 13, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE:EVT, MDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) TODAY ANNOUNCED FINANCIAL RESULTS FOR H1 2025, DEMONSTRATING CLEAR PROGRESS IN THE IMPLEMENTATION OF ITS NEW STRATEGY FOR SUSTAINABLE AND PROFITABLE GROWTH; HIGHLIGHTING JUST - EVOTEC BIOLOGICS' STRONG GROWTH AS IT TRANSITIONS TO AN ASSET-LIGHTER MODEL. DR CHRISTIAN WOJCZEWSKI, CHIEF EXECUTIVE OFFICER OF EVOTEC, SAID: "WE ARE FIRMLY ON TRACK WITH THE EXECUTION OF OUR STRATEGY: EVOTEC IS MAKING MEANINGFUL STRIDES TOWARD SUSTAINABLE AND PROFITABLE GROWTH.

EVOTEC SE REPORTS H1 2025 RESULTS: STRONG PROGRESS ON STRATEGY EXECUTION

HAMBURG, DE / ACCESS NEWSWIRE / AUGUST 6, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE:EVT, MDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) WILL ANNOUNCE ITS HALF-YEAR INTERIM REPORT FOR THE FIRST SIX MONTHS OF 2025 ON WEDNESDAY, 13 AUGUST 2025. THE COMPANY IS GOING TO HOLD A CONFERENCE CALL TO DISCUSS THE RESULTS AS WELL AS PROVIDE AN UPDATE ON ITS PERFORMANCE.

EVOTEC SE TO ANNOUNCE FIRST HALF-YEAR RESULTS 2025 ON 13 AUGUST 2025

HAMBURG, DE / ACCESS NEWSWIRE / JULY 30, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, MDAX/TECDAX, PRIME STANDARD, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) ANNOUNCES THE SIGNING OF A NON-BINDING AGREEMENT WITH SANDOZ AG (SIX:SDZ)(OTCQX:SDZNY) REGARDING THE POTENTIAL SALE OF JUST - EVOTEC BIOLOGICS EU IN TOULOUSE, FRANCE, FOR A CONSIDERATION OF ABOUT US$ 300 M IN CASH. IN ADDITION, THE PLANNED TRANSACTION TERMS INCLUDE FURTHER TECHNOLOGY RELATED CONSIDERATION, FUTURE DEVELOPMENT REVENUES, MILESTONES AND PRODUCT ROYALTIES.

EVOTEC SE AND SANDOZ AG PLANNING POTENTIAL SALE OF JUST - EVOTEC BIOLOGICS TOULOUSE SITE

EVOTEC SE AND SANDOZ AG SIGNED A NON-BINDING TERM SHEET ON A PLANNED SALE OF JUST - EVOTEC BIOLOGICS EU IN TOULOUSE TO SANDOZ UNDER THE PROPOSED DEAL EVOTEC WOULD TRANSFER BIOSIMILAR MANUFACTURING CAPABILITIES TO ENABLE SANDOZ TO PRODUCE BIOSIMILAR MEDICINES USING JUST - EVOTEC BIOLOGICS' ADVANCED CONTINUOUS MANUFACTURING TECHNOLOGY THE DEAL TERMS INCLUDE THE PURCHASE PRICE OF THE SITE FOR AROUND US$ 300 M IN CASH, AND IN ADDITION WILL INCLUDE FURTHER TECHNOLOGY RELATED CONSIDERATION, FUTURE DEVELOPMENT REVENUES, MILESTONES AND PRODUCT ROYALTIES PLANNED TRANSACTION MARKS MAJOR MILESTONE IN EVOTEC'S STRATEGY TO CREATE ASSET-LIGHTER BUSINESS MODEL LEVERAGING HIGH-MARGIN OFFERINGS, WITH JUST - EVOTEC BIOLOGICS REMAINING CORE BUSINESS FOR EVOTEC TRANSACTION IS EXPECTED TO IMMEDIATELY IMPROVE EVOTEC'S SHORT-, MID-, AND LONG-TERM REVENUE MIX, PROFIT MARGINS, AND CAPITAL EFFICIENCY HAMBURG, DE / ACCESS NEWSWIRE / JULY 30, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, MDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) TODAY ANNOUNCED THE SIGNING OF A NON-BINDING AGREEMENT WITH SANDOZ AG (SIX:SDZ)(OTCQX:SDZNY) REGARDING THE POTENTIAL SALE OF JUST - EVOTEC BIOLOGICS EU, WHICH OWNS THE J.POD BIOLOGICS MANUFACTURING FACILITY IN TOULOUSE, FRANCE, AND TO GRANT ACCESS TO ITS PROPRIETARY PLATFORM FOR INTEGRATED DEVELOPMENT AND ADVANCED CONTINUOUS MANUFACTURING OF BIOLOGICS VIA A TECHNOLOGY LICENSE. THE SITE HAS BEEN CUSTOMISED AND DEDICATED ENTIRELY TO SANDOZ SINCE JULY 2024, AND THE TRANSACTION IS A NATURAL PROGRESSION IN AN ALREADY SUCCESSFUL PARTNERSHIP.

EVOTEC AND SANDOZ EVOLVE THEIR STRATEGIC PARTNERSHIP AND AGREE ON POTENTIAL SALE OF JUST - EVOTEC BIOLOGICS TOULOUSE SITE

SUCCESSFUL EXECUTION OF NEW STRATEGY FOR SUSTAINABLE AND PROFITABLE GROWTH LEADING TO CHANGING REVENUE MIX WITH STRONG DEMAND FOR EVOTEC'S DIFFERENTIATED PLATFORMS HIGH-MARGIN TECHNOLOGY LICENSE REVENUES EXPECTED TO HAVE A STRONGER IMPACTTHAN ANTICIPATED SIGNIFICANT COST OPTIMIZATION IN EXCESS OF INITIAL TARGETS FROM PRIORITY RESET SHARED R&D BASE BUSINESSCONTINUES TO NAVIGATE IN A CHALLENGING MARKET ENVIRONMENT H1 2025 GROUP REVENUES BELOW EXPECTATIONS; ADJ. EBITDA BROADLY IN LINE WITH EXPECTATIONS REVENUE GUIDANCE ADJUSTED; R&D AND ADJUSTED EBITDA GUIDANCE UNCHANGED, REFLECTING IMPROVED REVENUE MIX AND COST DISCIPLINE EVOTEC CONFIRMS ITSOUTLOOK 2028 HAMBURG, DE / ACCESS NEWSWIRE / JULY 21, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, MDAX/TECDAX, ISIN: DE0005664809; NASDAQ:EVO) TODAY ANNOUNCED THAT IT HAS UPDATED ITS REVENUE GUIDANCE FOR THE FISCAL YEAR 2025.

EVOTEC ADJUSTS REVENUE GUIDANCE AND CONFIRMS PROFIT GUIDANCE ANTICIPATING A MORE PROFITABLE REVENUE MIX

HAMBURG, DE / ACCESS NEWSWIRE / JULY 21, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, MDAX/TECDAX, PRIME STANDARD, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) ANNOUNCES THAT IT HAS UPDATED ITS REVENUE GUIDANCE FOR THE FISCAL YEAR 2025. GUIDANCE ON R&D EXPENSES AND ADJUSTED EBITDA REMAINS UNCHANGED.

EVOTEC SE ADJUSTS REVENUE GUIDANCE WHILE CONFIRMING PROFIT GUIDANCE

NURTURE-AKI IS A NOVEL OBSERVATIONAL STUDY THAT COLLECTS LONGITUDINAL DATA AND BIOLOGICAL SAMPLES FROM FULLY CONSENTED ACUTE KIDNEY INJURY ("AKI") PATIENTS, DEVELOPED AS PART OF A RESEARCH CONSORTIUM LED BY KIDNEY RESEARCH UK THE STUDY FOCUSES ON 3 CLEARLY DEFINED COHORTS: AKI OF IATROGENIC ORIGIN (FOLLOWING CARDIAC SURGERY), AKI TO CHRONIC KIDNEY DISEASE ("CKD") TRANSITION AND PEDIATRIC AKI. THIS PARTNERSHIP WILL ENABLE EVOTEC TO UNDERSTAND HUMAN DISEASE PROGRESSION ON A MOLECULAR LEVEL AND TO PERFORM TARGETED DRUG DISCOVERY IN THE FIELD OF AKI.

EVOTEC JOINS NURTURE-AKI CONSORTIUM TO GAIN MULTI-OMICS-BASED MOLECULAR UNDERSTANDING OF ACUTE KIDNEY INJURY

GATES FOUNDATION SUPPORTS EVOTEC WITH A $ 2.5 M GRANT TO GENERATE CRITICAL DATA SUPPORTING DEVELOPMENT OF NEXT GENERATION TUBERCULOSIS DRUG COMBINATIONS. THE COLLABORATION CONTINUES A SUCCESSFUL PARTNERSHIP ON EVALUATING NEW TREATMENT REGIMENS AIMED AT REDUCING TREATMENT DURATION AND OVERCOMING RESISTANCE TO CURRENT THERAPIES.

EVOTEC RECEIVES $ 2.5 M GRANT TO GENERATE NEXT GENERATION TUBERCULOSIS TREATMENTS

GROUP REVENUES OF  200 M, ON TRACK TOWARDS GUIDANCE; SHARED R&D WITH SIMILAR TREND AS 2024; JUST - EVOTEC BIOLOGICS WITH CONTINUING GROWTH MOMENTUM STRONG PROGRESS IN STRATEGIC PROTEIN DEGRADATION PARTNERSHIP WITH BRISTOL MYERS SQUIBB STRATEGY BUILDING ON TECHNOLOGY AND SCIENCE LEADERSHIP: FOCUS ON HIGH-GROWTH, HIGH-VALUE SEGMENTS, SIMPLIFYING THE BUSINESS MODEL AND FOSTERING OPERATIONAL EXCELLENCE 2025 GUIDANCE AND 2028 OUTLOOK CONFIRMED HAMBURG, DE / ACCESS NEWSWIRE / MAY 6, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE:EVT, MDAX/TECDAX, ISIN: DE0005664809; NASDAQ: EVO) TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR Q1 2025, HIGHLIGHTING PROGRESS IN STRATEGIC PARTNERSHIPS AND IMPLEMENTATION OF MEASURES TO GENERATE SUSTAINABLE PROFITABLE GROWTH. DR CHRISTIAN WOJCZEWSKI, CHIEF EXECUTIVE OFFICER OF EVOTEC, SAID: "WITH  200 M OF REVENUES WE ENDED Q1 2025 SLIGHTLY AHEAD OF OUR EXPECTATION, DESPITE A SOFT DRUG DISCOVERY MARKET ENVIRONMENT.

Evotec SE

EVO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Evotec SE

EVO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EVO